Biotek-snakken — Oktober 2019
-
Tak peter12, https://biontech.de/science/pipeline
-
Det ser faktisk ud som de prøver det af sammen med Artezolizumab i et fase 1 program https://clinicaltrials.gov/ct2/show/NCT03313778?term=mRNA-4157&draw=2&rank=2
-
Jeg lukkede Bioporto gruppen. Der var nul trafik. Det samme gør jeg med Gomspece. Dem som ønskede den har ikke skrevet i den overhovedet.
-
-
Zymeworks also has ambitious plans in GEA, where it will need its efficacy results to rise to the challenge; with partner BeiGene, the company is planning a registrational trial in GEA to treat HER2-positive patients in the first line setting, running a head-to-head comparison against Herceptin.
-
Antistoffer med dobbelt virkning https://www.proinvestor.com/index.php?p=debat_1&postid=78487
-
Zymeworks Wins Best ADC Platform Technology Award for ZymeLink » ADC Review
Zymeworks has won the 6th Annual World ADC Awards in the Best ADC Platform Technology Category with ZymeLink™, a next-generation ADC platform technology which includes a suite of proprietary cytotoxins, stable linkers, and conjugation technologies compatible with traditional antibodies and proteins.
ADC Review (www.adcreview.com)
-
-
Fremragende Sukkeralf.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind